People with a personal or family history of medullary cell carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) should avoid semaglutide
Ozempic is injected once weekly, but it has a long half-life
As of November 2024, the MDL is progressing with ongoing discovery and motion hearings, and new cases continue to be added
It mimics the action of the glucagon-like peptide-1 (GLP-1) hormone, which stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite, leading to better blood sugar control and weight loss
In STEP 1-3 clinical trials, a weekly dose of 2.4 mg semaglutide resulted in a 49% reduction in C-reactive protein (CRP) levels, while a 1 mg weekly dose led to a 42% decrease, compared to placebo after 68 weeks
Monitoring for Side Effects Follow-up visits help ensure: Proper dose adjustments Management of nausea Observation of appetite changes Safe long-term use Thus, Thailand maintains strict prescription requirements to ensure safe usage
